<DOC>
	<DOCNO>NCT00269828</DOCNO>
	<brief_summary>This randomize , open-label , multinational , phase III study woman histologically- cytologically-confirmed advanced NSCLC chemotherapy naïve PS 2 . Study drug administer day 1 21 day cycle</brief_summary>
	<brief_title>A Survival Study Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy .</brief_title>
	<detailed_description>See Summary</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Female . 2 . Histologically cytologicallyconfirmed diagnosis NSCLC . 3 . ECOG performance score 2 . 4 . Patients meet one follow criterion : Stage IIIB candidate combine modality therapy ( primary radiation therapy surgery ) , Stage IV . 5 . Age great equal 18 year . 6 . Adequate bone marrow function 7 . Adequate renal function 8 . Adequate hepatic function 9 . Patients know brain metastasis must receive standard antitumor treatment CNS metastasis define site ’ institutional standard . 10 . Patients major surgery must fully recover surgery . 11 . Ability comply visit schedule assessment require protocol . 12 . For patient reproductive potential , commitment use adequate contraception . 13 . Signed approve informed consent , understand study procedure . 14 . Agreement begin study therapy within 8 calendar day randomization . 1 . Any intolerance polyLglutamic acid , Poloxamer 188 , dibasic sodium phosphate , monobasic sodium phosphate ( excipients CT2103 ) . 2 . Evidence small cell carcinoma , carcinoid , mixed small cell/nonsmall cell histology . 3 . Any prior systemic chemotherapy treatment lung cancer . This include systemic radiosensitizers use treat brain metastasis biologic agent . 4 . Concurrent primary malignancy except carcinoma situ nonmelanoma skin cancer . 5 . Grade 2 great neuropathy . 6 . Evidence significant unstable neurological symptom within 4 week study randomization . ( If unstable neurologic symptom result brain metastasis , patient must meet inclusion criterion number 9 ) . 7 . Clinically significant active infection active therapy underway . 8 . Investigational therapy within 4 week randomization , unless local requirement stringent . 9 . Unstable medical condition include unstable angina myocardial infarction within past 6 month randomization . Patients evidence cardiac conduction abnormality eligible cardiac status stable . 10 . Pregnant woman nurse mother . 11 . Any circumstance time study entry would preclude completion study require followup .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>PS 2</keyword>
	<keyword>female</keyword>
	<keyword>chemotherapy</keyword>
</DOC>